WEE1 Inhibitor Adavosertib Exerts Antitumor Effects on Colorectal Cancer, Especially in Cases with p53 Mutations
Cancers · 12.09.2024 · 16 (18) · 3136
DOI: 10.3390/cancers16183136 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 12.09.2024. Verfasst von Misa Ariyoshi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Hiroshima University Hospital, Hiroshima 734-0037, Japan. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Inhibition of WEE1, a key regulator of the G2/M checkpoint of the cell cycle, induces apoptosis by initiating mitosis without repairing DNA damage. However, the effects of WEE1 inhibitors on the tumor immune microenvironment in colorectal cancer (CRC) remain unclear. Here, we investigated the association between WEE1 expression and CRC clinicopathological features using surgically resected CRC specimens and assessed the antitumor effects of a WEE1 inhibitor using CRC cell lines and orthotopic transplantation mouse models. WEE1 expression was not correlated with the clinicopathological features of CRC. The WEE1 inhibitor suppressed cell proliferation in a concentration-dependent manner in all CRC cell lines. It also increased the percentage of cells in the G2/M phase and apoptotic cells, especially in cell lines with p53 mutations, but did not alter these cell percentages in most p53 wild-type cell lines. In the orthotopic mouse model of CRC, tumor volume was significantly reduced in the WEE1 inhibitor-treated group compared to that in the control group. RNA sequencing and immunohistochemistry analyses of mouse tumors revealed that treatment with the WEE1 inhibitor activated tumor immunity and suppressed stromal reactions. These results demonstrate the potential antitumor effects of WEE1 inhibitors in CRC, particularly in patients with p53 mutations.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology, Hiroshima University Hospital, Hiroshima 734-0037, Japan.
ORCID-Profile: Misa Ariyoshi, Hidehiko Takigawa
Zitieren
APA
Ariyoshi, M., Yuge, R., Kitadai, Y., Shimizu, D., Miyamoto, R., Yamashita, K., Hiyama, Y., Takigawa, H., Urabe, Y., & Oka, S. (2024). WEE1 Inhibitor Adavosertib Exerts Antitumor Effects on Colorectal Cancer, Especially in Cases with p53 Mutations. Cancers, 16(18), 3136. https://doi.org/10.3390/cancers16183136
Vancouver
Ariyoshi M, Yuge R, Kitadai Y, Shimizu D, Miyamoto R, Yamashita K, et al. WEE1 Inhibitor Adavosertib Exerts Antitumor Effects on Colorectal Cancer, Especially in Cases with p53 Mutations. Cancers. 2024;16(18):3136. doi:10.3390/cancers16183136
BibTeX
@article{Ariyoshi2024,
author = {Ariyoshi, Misa and Yuge, Ryo and Kitadai, Yuki and Shimizu, Daisuke and Miyamoto, Ryo and Yamashita, Ken and Hiyama, Yuichi and Takigawa, Hidehiko and Urabe, Yuji and Oka, Shiro},
title = {WEE1 Inhibitor Adavosertib Exerts Antitumor Effects on Colorectal Cancer, Especially in Cases with p53 Mutations},
journal = {Cancers},
year = {2024},
volume = {16},
number = {18},
pages = {3136},
doi = {10.3390/cancers16183136}
}
EUVIMED